Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company focused on transforming cancer treatment through cutting-edge immunotherapies. By leveraging its proprietary Amphiphile (AMP) platform, Elicio is developing vaccines and immunotherapies targeting aggressive cancers such as pancreatic, colorectal, and head and neck cancers.
The AMP platform uniquely targets and delivers immunogens directly to the lymphatic system, amplifying the body's immune response to fight cancer and prevent its recurrence. This innovative approach aims to unlock the full potential of the human immune system, resulting in enhanced anti-tumor functionality and long-term protective memory.
Recent achievements include:
- The commencement of initial patient studies for its lead amphiphile vaccines targeting various cancers in early 2020.
- Ongoing Phase 1 and Phase 2 trials for ELI-002, a novel cancer vaccine targeting mutant KRAS-driven tumors.
- The publication of promising preclinical and clinical data which demonstrate the AMP platform's potential in enhancing T cell responses and eradicating solid tumors.
Financial updates reveal continued investment in clinical trials and research, with expenses reflecting the company's robust R&D initiatives. Partnerships with renowned institutions like the University of Texas MD Anderson Cancer Center further bolster Elicio's research capabilities.
Looking forward, Elicio plans to advance its development pipeline, including the ELI-002 7P Phase 2 trial as a monotherapy for patients with pancreatic ductal adenocarcinoma (PDAC). The company remains committed to pioneering new cancer treatments and improving patient outcomes.
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced that its CEO and EVP will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference. The chat will be accessible via RSVP to a B. Riley Securities sales representative and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
News
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) announces the dosing of the first patient in the Phase 2 study of ELI-002 7P, a therapeutic cancer vaccine targeting seven common mutations in KRAS, at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research. The vaccine aims to treat pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. Elicio's proprietary AMP technology targets more mutations compared to other KRAS-targeted therapies, potentially benefiting a larger patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced promising results from the Phase 1 study of ELI-002 in Nature Medicine, demonstrating robust, polyfunctional, and durable KRAS-specific CD4+ and CD8+ T cell responses in cancer patients. The study showed an 84% reduction in tumor biomarkers, correlating with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is planned to start in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC, controlled by a member of Elicio’s Board of Directors. The gross proceeds of the private placement are expected to be approximately $7.0 million, with the net proceeds intended for the advancement of its development pipeline, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company is a clinical-stage biotechnology firm focusing on developing immunotherapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.04%
Tags
-
News
Rhea-AI Summary
ELTX: Elicio Therapeutics reports promising results for ELI-002 in pancreatic cancer treatment. Median relapse-free survival of 16.3 months and a significant reduction in risk of progression or death. Plans to initiate ELI-002 7P Phase 2 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
Rhea-AI Summary
Elicio Therapeutics announces promising data from the Phase 1 study of ELI-002 cancer vaccine in patients with mKRAS-driven pancreatic and colorectal cancers. 87% of patients had mKRAS-specific T cell responses and the strength of the response correlated with reduced risk of relapse and death. ELI-007 and ELI-008 vaccines also showed strong induction of tumor-antigen-specific T cell responses in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.06%
Tags
-
Rhea-AI Summary
Elicio Therapeutics to present updated data on ELI-002 and preclinical data on ELI-007 and ELI-008 at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Elicio Therapeutics announces promising preliminary relapse-free survival data for its cancer vaccine ELI-002. Preliminary data from the Phase 1 study shows an 86% reduction in the risk of progression or death in patients with large T cell responses. Elicio plans to initiate a randomized Phase 2 study in early 2024. No safety concerns were identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
Rhea-AI Summary
Elicio Therapeutics receives $2.6M grant for cancer vaccine research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
The current stock price of Elicio Therapeutics (ELTX) is $4.811 as of October 17, 2024.
What is the market cap of Elicio Therapeutics (ELTX)?
The market cap of Elicio Therapeutics (ELTX) is approximately 51.2M.
What is Elicio Therapeutics' core business?
Elicio Therapeutics focuses on developing innovative cancer immunotherapies using its proprietary Amphiphile (AMP) platform.
What is the AMP platform?
The AMP platform delivers immunogens directly to the lymph nodes to amplify the immune response against cancer.
What are Elicio's lead products?
Elicio's lead product is ELI-002, a cancer vaccine targeting mutant KRAS-driven tumors, currently in Phase 1 and Phase 2 trials.
What types of cancer does Elicio's AMP platform target?
Elicio's AMP platform targets aggressive cancers like pancreatic, colorectal, and head and neck cancers.
What recent progress has Elicio made in its research and development?
Elicio has started initial patient studies for its lead vaccines, published promising preclinical data, and is conducting Phase 1 and Phase 2 trials for ELI-002.
Who are some of Elicio's research partners?
Elicio has partnered with renowned institutions like the University of Texas MD Anderson Cancer Center.
What is the financial status of Elicio Therapeutics?
Elicio continues to invest in R&D with increased expenses due to ongoing trials and research, reflecting its commitment to developing innovative cancer treatments.
What is the significance of ELI-002 7P formulation?
ELI-002 7P targets seven common KRAS mutations, increasing potential patient coverage and aiming to reduce cancer recurrence.
What are the future plans for Elicio Therapeutics?
Elicio plans to continue advancing its development pipeline, including Phase 2 trials for ELI-002 7P, and exploring new immunotherapy candidates.
How does Elicio aim to enhance the immune system's cancer-fighting capabilities?
Elicio’s AMP platform directs therapeutic payloads to lymph nodes, optimizing immune responses to recognize and eliminate tumor cells.
Elicio Therapeutics, Inc.
Nasdaq:ELTX
ELTX Rankings
ELTX Stock Data
51.18M
10.78M
28.13%
6.1%
0.62%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON